Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin with BuCyE Conditioning and ASCT for B-cell NHL
NCT00336843Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Nov 2005
- Primary completion
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in B-cell non-Hodgkin lymphoma, sponsored by Asan Medical Center. Primary endpoint: Event-free survival. Started Nov 2005; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00336843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00336843.